Sage Journals: Discover world-class research

Abstract

Most of neurodegenerative diseases (NDD) have no cure. The common etiology of neurodegenerations is unclear. Air pollutant-gaseous formaldehyde is notoriously known to induce demyelination and cognitive impairments. Unexpectedly, an amount of formaldehyde has been detected in the brains. Multiple factors can induce the generation and accumulation of endogenous formaldehyde. Excessive formaldehyde can induce oxidative stress to generate H₂O₂; in turn, H₂O₂ promote formaldehyde production. Clinical investigations have shown that an abnormal high level of formaldehyde but low level of coenzyme Q10 (coQ10) was observed in patients with NDD. Further studies have proven that excessive formaldehyde directly inactivates coQ10, reduces the ATP generation, enhances oxidative stress, initiates inflammation storm, induces demyelination; subsequently, it results in neurodegeneration. Although the low water solubility of coQ10 limits its clinical application, nanomicellar water-soluble coQ10 exhibits positive therapeutical effects. Hence, nanopackage of coQ10 may be a promising strategy for treating NDD.

Keywords

neurodegenerative diseases demyelination endogenous formaldehyde coenzyme Q10 inflammation storm

Introduction

Neurodegenerative diseases (NDD) are a diverse group of neurological diseases characterized by neuron loss, demyelination, and irreversibly functional decline.¹ Typical NDD includes Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophiclateral sclerosis (ALS), cerebellar atrophy (CA), etc.² Substantial evidences suggest that mitochondrion plays a critical role in aging-related neurodegeneration. Both mutations in mitochondrial DNA and oxidative stress indeed accelerate the ageing process, which is a confirmed risk factor for NDD.² With the increasing trend of population aging, more people are suffered from NDD every year, affecting their quality of life in the world.³ Most of NDD have no cure. These diseases bring a heavy economic and social burden in the global. To explore the common etiology of neurodegeneration is urgently needed.

An kind of air pollutant, gaseous formaldehyde (FA), is notoriously known to induce cognitive impairments and demyelination in animals⁴ and humans.⁵ Unexpectedly, an amount of FA has been detected in the brains.^6,7 Multiple factors can induce the generation and accumulation of endogenous FA.⁸ In AD, amyloid-beta (Aβ) induces FA accumulation by binding with formaldehyde dehydrogenase (FDH) and inactivating it.⁹ Generally, FA induces oxidative stress, which generates hydrogen peroxide (H₂O₂);¹⁰ in turn, H₂O₂ enhances FA production and accumulation.¹¹ More worse, excessive FA directly inactivates mitochondrial coQ10, reduces the ATP generation,^12-14 enhances oxidative stress, initiates inflammation storm (ie release of IL-1, IL-6, TNF-α, etc.),^10,15 induces demyelination of neurons.¹⁶ Above data suggest that excessive FA is a critical endogenous factor for triggering NDD occurrence.

The central nervous system (CNS) is the main pathological sites of NDD, and urine is anatomically distant from CNS compared to other biological fluids, such as: cerebrospinal fluid (CSF) and plasma; therefore, the components in urine are not often considered to be a suitable biomarker for NDD. However, recent studies have indicated that urinary components may act as a source of NDD biomarkers if suitable markers are predetermined in urine and other samples of metabolic and proteomics approaches. A series of studies in recent years suggest the potential of urine as a source of NDD biomarkers.^17-22 Clinical investigations have demonstrated that patients with AD or PD^14,23,24 were often associated with an abnormal high level of endogenous FA but low level of coenzyme Q10 (coQ10, a powerful endogenous antioxidant).^25,26 Urinary FA levels are positively correlated with severe degree of AD,²³ and potentially act as a marker for predicting treatment efficacy.²⁷

Active compounds produced by the metabolism of the body provide a promising target to be evaluated as a potential therapy for various pathological conditions in NDD.²⁷ Among them, endogenous coQ10 is a key cofactor involved in mitochondrial oxidative phosphorylation and an effective endogenous antioxidant.²⁸ It has been found to exert neuroprotective effects against oxidative stress-induced damage and mitochondrial respiratory chain dysfunction in a variety of NDD.²⁹ This review provides evidence that coQ10 may be a potential drug target and/or biomarker in NDD.

Role of Endogenous Formaldehyde in Neurodegenerative Diseases

Formaldehyde and Alzheimer’s disease

Extensive evidence indicates that endogenous FA is mainly involved in the “one-carbon cycle” mediated by the 5,10-methylene tetrahydrofolate reductase (MTHFR),³⁰ which participates in some physiological and pathological functions. For example, low levels of active FA act as a memory-related molecule to regulate learning and memory.³¹ However, it at high concentrations acts as a protein degenerative agent to induce NDD, such as AD and ALS.^12-14 It has been proven that multiple factors, such as: age,^32-34 stress,³⁵ stroke,³⁶ diabetes,³⁷ virus infected,^38-42 clinical operation,⁴³ and some diets (deep-sea fish polluted with methyl mercury^44,45), can result in FA accumulation.⁸

Epidemiological investigations have shown that increasing age is the most critical risk factor for AD, with most cases in 65 years of age and older.⁴⁶ Disruption of FA metabolism during ageing lead to FA accumulation by increasing the activity of semicarbazide-sensitive amine oxidase (SSAO, a FA-generating enzyme) but decreasing the activity of FDH (a FA-degrading enzyme); especially, age-related FA induces tau hyperphosphorylation to form neurofibrillary tangels (NFTs) ^47,48 and inhibits N-methyl-D-asparate currents (NMDA-currents), thereby impairing cognitive functions.⁴⁹ In addition, mitochondrial damage has been found in sporadic and/or hereditary dementia patients,⁵⁰ and the polymorphism of mitochondrial aldehyde dehydrogenase 2 (ALDH2) is an important risk factor for late-onset AD in the Chinese population.⁵¹ These findings suggest that ALDH2 mutation-associated FA overload accelerates cognitive impairments in AD.³¹ In a survey of 604 healthy older adults, the levels of age-associated FA in the urine were negatively correlated with cognitive ability.²³ In a double blind study, urinary FA levels were substantially elevated in 91 patients with dementia and slightly elevated in 50 patients with mild cognitive impairment (MCI).⁷ The levels of urinary FA were negatively related to the scores of simple mental state examination (MMSE, Rs = −.441, P < .0001).⁷ Age-related FA is considered to be a direct trigger of sporadic dementia in the elderly.⁴⁹

Recent studies have revealed that amyloid-beta (Aβ) not only induces FA production through oxidative demethylation of serine residues in vitro, but also inhibits FA degradation, leading to FA accumulation by reducing the activity of FDH. In turn, FA promotes Aβ aggregation, exerts neurotoxicity, and causes cognitive deficits in early-onset familial and late-onset AD. Hence, there is a vicious cycle between FA accumulation and Aβ assembly, which plays an important role in the deterioration of AD.¹² To make matters worse, FA induces Aβ deposition in the extracellular space (ECS) of brain, thereby blocking the influx of drugs (dissolved in the interstitial fluid) into damaged neurons in the deep cortex.⁵² Thus, excessive FA is a trigger for Aβ oligomerization intracellularly and fibrillation extracellularly in AD.

Formaldehyde and Parkinson’s Disease

PD is characterized by loss of substantial nigra neurons, resulting in striatum dopamine deficiency.⁵³ The aggregation of α-synuclein and mitochondrial dysfunction appear to be synergistic features of PD, and mitochondrial dysfunction is associated with α-synuclein aggregation in the degenerating neurons in PD.⁵⁴ It is well known that α-synuclein can induce oxidative stress and reactive oxygen species (ROS) generation,^55,56 which is accompanied by H₂O₂ production;^12,57,58 in turn, H₂O₂ promotes FA generation and accumulation rapidly (Figure 1).⁵⁹

Figure 1.

Roles of formaldehyde and coenzyme Q10 in the etiology of neurodegenetive disease. Abbreviation: ATP, adenosine triphosphate; Aβ, amyloid-beta; Cyt-c, cytochrome C; FA, formaldehyde; IL-1, interleukin-1; IL-6, interleukin-6; Q10, coenzyme Q10; Nano-Q10, nano-packaged coenzyme Q10; ROS, reactive oxygen species; α-syn, α-synuclein; TCA, tricarboxylic acid cycle; TNF-α, tumor necrosis factor-α; VDAC: voltage-dependent anion selective channel.

The typical pathological features of PD include abnormal accumulation of α-synuclein, deregulation of metal ion metabolism, oxidative stress, mitochondrial dysfunction, and neurotransmitter defects in the striatum and substantia nigra.^53,60,61 The FA-degrading enzyme- ALDH2 has been found to be decline in both activity and expression in PD patients,⁶² and FA can have spontaneous chemical reaction with dopamine in vitro,⁶³ suggesting that excessive FA may be the direct reason of dopamine deficiency in the striatum and substantia nigra. Previous study revealed that FA-crosslinked α-synuclein oligomers can serve as important calibrators to facilitate comparative and normalized α-synuclein biomarker studies.⁶⁰

In addition, FA-crosslinked α-synuclein oligomers can be used as important calibrators to facilitate comparative and normalized α-synuclein biomarker studies.⁶⁰ Brain cells of patients with PD exhibit dysglycemia,⁶⁴ and excess FA promotes hyperglycemia and cognitive impairment through interaction with insulin,⁶⁵ suggesting that FA may be involved in dysglycemia in PD patients. Hypermethylation may be associated with the pathogenesis of some PD cases, some genes in PD patients have higher levels of methylation-active.⁶⁶ Excessive protein carboxy-methylation, increasing FA may cause neurotoxic effects through the potent metabolite FA to play a critical role in the sadenosyl-methionine (SAM)-induced PD-like neuronal damage and aging.⁶¹

Formaldehyde and Multiple Sclerosis

In the brains of patients with NDD, such as: AD or MS, the expression of SSAO (a FA-producing enzyme) is raised, and serum FA levels are also elevated.^14,67 Some human subjects who had suffered from methanol poisoning often exhibited the symptoms of MS (such as: demyelination and cognitive decline), which may be the effects of the oxidation of methanol to FA and subsequent protein modifications leading to immune responses.⁶⁷ Gaseous FA exposures are considered to be a possible risk factor for the development of ALS.⁶⁸ In fact, hypoxia can promote a massive accumulation of endogenous FA in the brains.⁶⁹ Consistently, hypoxia-like tissue damage in the type III of MS lesions may be caused by mitochondrial damage,⁷⁰ because FA exerts potent cytotoxicity, at least in part, by inducing oxidative stress, mitochondrial dysfunction, and ultimately apoptosis.⁷¹ Hence, FA-induced mitochondrial damage contributes to the occurrence of MS.

Role of Endogenous Coenzyme Q10 in Neurodegenerative Diseases

CoQ10 (also named ubiquinone 50) composed by a quinone ring, that forms the head, and a hydrofobic tail, which contains 10 isoprenoid units, is a lipophilic, redox active molecule located in all cellular membranes. It can be found in all the tissues, but the highest concentrations of it are detected in heart, brain, kidney and liver. CoQ10 is naturally present in the vegetables. CoQ10 can accept 1 or 2 electrons both to be transferred into the respiratory chain, from complex I and II to complex III for ATP production. It is a powerful antioxidant that protects cell from ROS-induced damage in 2 ways: directly reacting with ROS and regenerating α-tocopherol and ascorbate. The reduced form, ubiquinol, is a powerful antioxidant that prevents oxidative damage by free radicals, including oxidation of lipids within the mitochondrial membrane. Hence, coQ10 strongly support the function of mitochondria.⁷² Previous study quantified plasma COQ10 by ultra-performance liquidchromatography-mass spectrometry (UPLC-MS) and recruited 40 patients with multiple system atrophy (MSA), 30 patients with Parkinson’s disease (PD), and 30 healthy participants.⁷³ Plasma CoQ10 levels were significantly altered in MSA, PD and control groups (P = 0.001). The cut-off point for differentiation between MSA patients and controls was maximal at 1710 ng/mL, with a sensitivity of 40 % and specificity of 97.5 % for the receiver operating characteristic curve (ROC curve).⁷³ Using the d6-CoQ10 internal standard, a sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method can be developed to accurately determine total CoQ10 levels.⁷³ Clinical applications of CoQ10 determination in cerebrospinal fluid (CSF) include identifying patients with CoQ10 deficiency in the brains and monitoring CoQ10 levels in the CSF after supplementation of it.⁷⁴

CoQ10 and Alzheimer’s Disease

Substantial evidence has supported the viewpoint that the critical role of oxidative stress and deficits in energy metabolism in the pathogenesis of various NDD.²⁸ Oxidative stress has been found to promote Aβ deposition in AD.⁷⁵ Notably, coQ10, an essential cofactor involved in mitochondrial oxidative phosphorylation, is also a potent antioxidant. Mitochondrial dysfunction has been considered to link with pathological changes in AD.⁷⁶ Its defects mainly occur in the complexes I, IV, and V of the electron transport chain, resulting in the production of free radicals.⁷⁷ Endogenous coQ10 is part of the electron transport chain,⁷⁸ suggesting that coQ10-related mitochondrial dysfunction contributes to the occurrence of AD.

In AD patients, the concentrations of coQ10 and FA varied inversely, suggesting that there is a spontaneous chemical reaction between these two compounds.^79,80 As an endogenous antioxidant, coQ10 has been found to decrease aldehyde levels,⁵⁷ and is an endogenous FA scavenger.¹² Using gas chromatography-tandem mass spectrometry (GC-MS/MS), it has been found that one molecule coQ10 have chemical reaction with three molecules of FA (Figure 1).⁸¹ In addition, FA works with Aβ synergistically to inhibit cytochrome c oxidase (CcOX) activity and to reduce coQ10 levels, thereby decreasing adenosine triphosphate (ATP) production, and inducing neuronal death irreversibly.¹² Above data also indicate that the reaction between FA and coQ10 may be the fundamental reason of coQ10 deficiency in NDD.

CoQ10 and Parkinson’s Disease

Loss of the dopaminergic neurons in the striatum and substantia is considered to be a critical factor for promoting PD occurrence. Recent studies have found that nitration and nitrosylation of α-synuclein, is closely related to PD. It is a small protein made of 140 amino acids, mainly expressed in CNS, in neocortex, thalamus, hippocampus, substantia nigra and cerebellum. It is present in the membrane of mitochondria in normal dopaminergic neurons. However, under over-expression conditions, α-synuclein monomers are aggregated into oligomers, which cause toxicity in response to subtoxic concentrations of mitochondrial toxins. It is widely known that α-synuclein induces a strong oxidative stress to produce ROS (a main pathological moment in PD). ROS is a family of extremely reactive molecules which have an unpaired electron that reacts with other substances. The 3 main components of ROS are superoxide (O₂-), H₂O₂ and hydroxyl radical (·HO). H₂O₂ is considered to be a principal compound related to cytotoxicity in dopaminergicneurons.⁸²

The levels of markers of oxidation are increased in substantia nigra samples of PD patient, making a relationship between this kind of damage and the onset of disease. CoQ10 levels were reported to be 33 % lower in the blood and platelet mitochondria of PD patients compared to age- and sex-matched controls.⁸³ Mitochondrial dysfunction is believed to be the root cause of the death of dopamine-producing neurons. Since coQ10 (an endogenous antioxidant for reducing ROS) is the integral component of mitochondria, its deficiency can increase the risk of dopaminergic-neuron death in the brain and can lead to the development of PD.⁸⁴

CoQ10 and Multiple Sclerosis

A systematic review has indicated that MS patients, especially those with more severe condition, had lower levels of coQ10 in the blood but higher levels of oxidative stress, when compared with controls.⁸⁵ Since MS patients were often accompanied by endogenous coQ10 deficiency, oral supplementation of coQ10 may contribute to the treatment of MS. Especially, coQ10 can act as a powerful antioxidant and anti-inflammatory compound capable of crossing the blood-brain barrier when administered peripherally (eg, orally or intravenously).⁸⁵

Excessive FA has been found in the blood of MS patients, and reduction of FA by glycine improves the pathological characteristics of MS.⁸⁶ Especially, FA can induce demyelination,⁵ and inflammation storm (stimulate the release of IL-1, IL-6 and TNFα).^10,15 Notably, IL-1, IL-6 and TNFα have been found to promote the demyelination of neurons (Figure 1).¹⁶ CoQ10 application has been found to prevent demyelination and increase re-myelination in a chronic cuprizone (CPZ) model of MS. It attenuates CPZ-induced stress oxidative and inhibits inflammatory biomarkers.⁸⁷ CoQ10-scavenged FA may be a critical reason for treating MS in this CPZ-model.¹² Similarly, in another autoimmune MS model of the experimental autoimmune encephalomyelitis (EAE), coQ10 can reduce the levels of IL-1, IL-6 and TNFα.⁸⁸ In a clinical study of 24 patients with relapsing-remitting MS, coQ10 markedly reduces inflammatory factors and decreases oxidative stress.^89,90

CoQ10 for Treating Neurodegenerative Diseases

CoQ10 and Alzheimer’s disease

The current findings indicate that coQ10 treatment provides neuroprotection through its antioxidant activity against the adverse effects of Aβ on hippocampus synaptic plasticity.⁷⁵ Given the potent antioxidant propensity of coQ10, some investigations have been carried out to assess endogenous coQ10 status in AD patients.⁹¹ Previous study showed that coQ10-treated mice have better cognitive performance in the Morris water maze test than wild-type mice, and coQ10 alleviates the pathological characters of AD.⁹² Encouragingly, an enhanced water soluble nano-coQ10,⁹³ or a nano-packaged coQ10 with a diameter of 30 nm has been proven to directly degrade FA, reduce intracellular Aβ oligomers and extracellular senile plaques (SPs); subsequently, it rescues memory functions in APP/PS1 mice.¹² Scavenging FA with resveratrol also reduces the formation of SPs and improves cognitive behavior in transgenic AD mice.⁴⁹ Thus, coQ10 as an endogenous FA scavenger may be used to treat AD patients.

As people ageing, the ability of generating coQ10 is gradually declining, especially in people over the age of 50. Meanwhile, the capacity of reducing coQ10 synthesis reflects an increased risk of developing neurological diseases.²⁵ In vitro study using human venous endothelial cells (HVECs) suggest that coQ10 supplementation has a therapeutic potential in preventing the deleterious effects of Aβ deposition in the early asymptomatic stages of AD, which may slow the progression of neuropathology.⁹⁴ Pretreatment of HVECs with coQ10 prevents Aβ-induced cytotoxicity and oxidative damage by inhibiting Aβ trafficking and accumulation in the mitochondria.⁹⁴ Meanwhile, coQ10 supplementation has been found to dramatically reverse these consequences and increase serum total antioxidant capacity.⁷⁵

CoQ10 and Parkinson’s Diseases

Some preclinical studies of in vitro and in vivo models of PD have shown that coQ10 protects the nigrostriatal dopaminergic system.⁹⁵ Compare with age-/sex-matched controls, PD subjects had an abnormal lower levels of coQ10 in mitochondria.⁹⁶ Consistently, deficiency in the brain coQ10 has been observed in PD patients,⁹⁷ because coQ10 contents are decreased in the plasma and platelets in PD patients than healthy controls.^25,26 Hence, to a certain degree, supplementation of coQ10 could help to ameliorate in the symptom severity,⁹⁵ and to improve in color vision in PD patients.^98,98

A Phase II clinical trial has shown that oral coQ10 prevents functional decline in patients with early PD. CoQ10 supplementation also has a significant mild symptomatic benefit on PD symptoms,⁹¹ and markedly improved the performance Farnsworth–Munsell 100 Hue test (FMT).⁹⁹ Remarkably, there is not any assessment for the presence of underlying coQ10 deficiency in PD patients prior to initiation of coQ10 application before 2014.¹⁰⁰ This may also explain why the clinical efficacy of coQ10 has rarely been reported previously.⁹¹

CoQ10 and Multiple Sclerosis

Mitochondrial dysfunction and oxidative stress occur early in all major neurodegenerative diseases, oxidative stress is a driver of MS pathology.¹⁰¹ There is convincing evidence that both of these two factors play a causal role in the pathogenesis of MS.¹⁰¹ In neurological diseases, defeciency in coQ10 status have been reported, leading to disturbances in antioxidant status and mitochondrial dysfunction, often induces severe neuronal degeneration.^29,102,103 Elevated levels of serum FA in MS patients accumulate neurotoxicity,¹⁰⁴ and deplete endogenous Q10,⁸¹ and result in neuronal damage, suggesting that Q10 can scavenge excessive FA in MS.

Some studies have found that there is a positive beneficial effect of coQ10 application on fatigue status in healthy, fibromyositis, statin-related fatigue, MS, and end-stage heart failure subjects.⁸⁵ A clinical investigation showed that application of 500 mg/day of coQ10 for three months can alleviate fatigue symptoms in MS patients (32 ± 7.65 years).⁸⁹ CoQ10 supplementation could improve the scavenging activity, reduced oxidative damage, and induce a shift towards a more anti-inflammatory milieu, in the peripheral blood of relapsing–remitting MS patients treated with 44 μg IFN-β1 and coQ10.⁸⁵ In addition, 12-weeks coQ10 supplementation in MS patients can reduce peripheral oxidative stress,⁹⁰ inhibit inflammation form,⁸⁹ and ameliorate fatigue and depressive symptoms.¹⁰⁵

Summary and Outlook

The earliest of all references dates back to 1982 and the most recent to 2022. The early diagnosis, prognosis and monitoring of NDD are still far from meeting the requirements of precision medicine, and clinical treatments do not approach to the idea efficacy so far.¹⁰⁶ Since the common pathological areas of NDD are in the brains, the sampling the living tissue is often unrealizable or difficult for accurately diagnosing of NDD. Hence the development of reliable biomarkers for NDD diagnosis is urgently needed.²⁷ A large bodies of evidence have shown that there is a “preclinical” phase in patients with NDD, possibly starting several years before a subject’s diagnosis. Although their behaviors seem to be normal, their brains have extensive pathological changes.^107,108 Recently, a non-invasive fluorescence spectrophotometry with ethyl cyanoacetate (FS-ECA) method has been developed to detect coQ10 in the urine samples of AD patients, and this method has the potential to replace HPLC to quantify blood coQ10 concentration (Figure 2).²⁴ These studies provide a good basis for rapidly detecting the biomarkers combined with urinary FA and coQ10 in NDD.

Figure 2.

Levels of coenzyme Q10 and FA in the urine during human ageing. Red line: urine FA levels; Yellow line: urine Q10 levels; blue line: cognitive status. Abbreviation: FA, formaldehyde; Q10, coenzyme Q10.

It is widely known that mitochondria is the primary site of initiation and spread of disease processes.¹⁰⁹ Mitochondrial dysfunction-induced neuronal death is a joint pathway of all the NDD.^110,111 These deleterious aggregated proteins, such as: Aβ, α-synuclein, can result in oxidative stress, which produces a large amount of H₂O_2;¹¹⁰ in turn, H₂O₂ induces the rapid production of FA.¹¹ Meanwhile, FA rapidly inactivates coQ10.¹² Hence, both excessive FA and coQ10 deficiency may be a principal reason for triggering mitochondrial degeneration and dysfunction. Research shows that the reaction ratio of FA and Q10 is about 3:1.¹² It is recommended that the Q10 concentration is about 0.17 mM when the FA pathological concentration is 0.5 mM. The daily supplemental Q10 content is about 364 mg for treating AD model mice. This concentration of Q10 was not over the doses (500 mg) presented in a previous study.¹¹²

Although natural coQ10 is low water soluble, a kind of enhanced water soluble nano-coQ10,⁹³ or the nano-packaged Q10 with a diameter of 30 nm can strengthen water solubility and alleviate the pathological characteristics and behaviors in AD model mice.¹² Gradually, some studies have introduced nano-packaged Q10 as a treatment, because nano-packaged Q10 has better water solubility and bioavailability compared to traditional Q10 drugs; the absorption rate of coenzyme-Q10 in solid lipid particles is approximately 3 times higher than that of direct oral coenzyme-Q10.¹¹³ Also, the ability to penetrate the blood-brain barrier was enhanced. Substantial evidence suggests that nanoparticle-based drugs can penetrate into the cerebral cortex for treating brain disorders.⁴⁹ A previous study has shown that 30-nm packed Q10 penetrates both the BBB and extrcellular space (ECS), and can be devoured by the neurons in the deep layer of the cortex, which reduces Aβ- and tau-related pathological characteristics and improves cognitive behaviors in APP/PS1 mice.¹² In addition, nano-packaged Q10 also increases neuronal activity.

In a word, the detection of endogenous FA and coQ10 contents is helpful to monitor the process of NDD, and supplementation of nano-packaged coQ10 may contribute to the treatments of NDD.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This research was funded by the National Natural Science Foundation of China (82071214), Beijing Natural Science Foundation (M21004), and the Fund of Talent Launch Project of Oujiang Laboratory (OJQDSP2022011).

ORCID iDs

Jinan Xu

Zhiqian Tong

References

Simren

Ashton

Blennow

Zetterberg

. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Curr Opin Neurobiol. 2020;61:29-39.

Ciaccio

. Biochemical Biomarkers and Neurodegenerative Diseases. Brain Sci. 2021;11(7):940.

Ghosh

. Biomarkers in Neurodegenerative Diseases. Biomedicines. 2022;10(2):215.

ZLC

Qiao

Yan

Yang

. Effect of inhaled formaldehyde on learning and memory of mice. Indoor Air. 2008;18(2):77-83.

Perna

Bordini

Deinzer-Lifrak

. A case of claimed persistent neuropsychological sequelae of chronic formaldehyde exposure: clinical, psychometric, and functional findings. Arch Clin Neuropsychol. 2001;16(1):33-44.

Heck

White

Casanova

. Determination of formaldehyde in biological tissues by gas chromatography/mass spectrometry. Biomed Mass Spectrom. 1982;9:347-353.

Tong

Zhang

Luo

, et al. Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. Neurobiol Aging. 2011;32:31-42.

Kou

Zhao

Cui

Han

Tong

. Formaldehyde toxicity in age-related neurological dementia. Ageing Res Rev. 2021;73:101512.

Yue

Mei

Zhang

, et al. New insight into Alzheimer's disease: Light reverses Abeta-obstructed interstitial fluid flow and ameliorates memory decline in APP/PS1 mice. Alzheimers Dement. 2019;5:671-684.

10.

Lino-dos-Santos-Franco

Correa-Costa

Durão

, et al. Formaldehyde induces lung inflammation by an oxidant and antioxidant enzymes mediated mechanism in the lung tissue. Toxicol Lett. 2011;207(3):278-285.

11.

Tao

Liao

Wang

, et al. In Situ Imaging of Formaldehyde in Live Mice with High Spatiotemporal Resolution Reveals Aldehyde Dehydrogenase-2 as a Potential Target for Alzheimer’s Disease Treatment. Anal Chem. 2021;94(2):1308-1317.

12.

Fei

Zhang

Mei

, et al. Degradation of FA reduces Aβ neurotoxicity and Alzheimer-related phenotypes. Mol Psychiatr. 2021;26(10):5578-5591.

13.

Roberts

Johnson

Cudkowicz

Eum

Weisskopf

. Job-related formaldehyde exposure and ALS mortality in the USA. J Neurol Neurosurg Psychiatr. 2016;87(7):786-788.

14.

Khokhlov

Zavalishin

Savchenko

Dziuba

. Disorders of formaldehyde metabolism and its metabolic precursors in patients with multiple sclerosis. Zhurnal nevropatologii i psikhiatrii imeni SS Korsakova. 1989;89(2):45-48.

15.

Gerin

Erman

Erboga

, et al. The effects of ferulic acid against oxidative stress and inflammation in formaldehyde-induced hepatotoxicity. Inflammation. 2016;39(4):1377-1386.

16.

Woodroofe

Cuzner

. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine. 1993;5(6):583-588.

17.

Seo

Son

Seol

. Increased DJ-1 in urine exosome of Korean males with Parkinson’s disease. BioMed Res Int. 2014;2014.

18.

Wang

Cui

Yang

, et al. Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer’s disease in patients with the apolipoprotein E ε4 genotype. Biomarkers. 2015;20(1):84-88.

19.

Yang

Xia

Zhang

. Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model. Cell Death Dis. 2014;5(5):e1217-e1217.

20.

Wang

West

. Caught in the act: LRRK2 in exosomes. Biochem Soc Trans. 2019;47(2):663-670.

21.

Wang

Liu

, et al. Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathologica Communications. 2017;5(1):1-13.

22.

Nam

Lee

J-Y

Lee

, et al. Detection and assessment of α-synuclein oligomers in the urine of Parkinson’s disease patients. J Parkinsons Dis. 2020;10(3):981-991.

23.

Zhou

, et al. Uric formaldehyde levels are negatively correlated with cognitive abilities in healthy older adults. Neurosci Bull. 2014;30(2):172-184.

24.

Fei

, et al. A rapid and non-invasive fluorescence method for quantifying coenzyme Q10 in blood and urine in clinical analysis. J Clin Lab Anal. 2020;34(4):e23130.

25.

Matsubara

. Serum coenzyme Q-10 level in parkinson syndrome. Biomed Clin Aspec of Coenzy Q. 1991:159-166.

26.

Shults

Haas

Passor

Beal

. Coenzyme Q10 level is reduced in mitochondria from Parkinsonian patients. Ann Neurol. 1997;42:61-65.

27.

Seol

Kim

Son

. Urinary biomarkers for neurodegenerative diseases. Experiml Neurobio. 2020;29(5):325.

28.

Spindler

Beal

Henchcliffe

. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatric Dis Treat. 2009;5:597.

29.

Cirilli

Damiani

Dludla

, et al. Role of coenzyme Q10 in health and disease: An update on the last 10 years (2010–2020). Antioxidants. 2021;10(8):1325.

30.

Burgos-Barragan

Wit

Meiser

, et al. Mammals divert endogenous genotoxic formaldehyde into one-carbon metabolism. Nature. 2017;548(7669):549-554.

31.

Tan

Tang

, et al. Endogenous formaldehyde is a memory-related molecule in mice and humans. Commun Biol. 2019;2(1):1-12.

32.

Qiang

Xiao

, et al. A novel mechanism for endogenous formaldehyde elevation in SAMP8 mouse. J Alzheimers Dis. 2014;40(4):1039-1053.

33.

Tong

Han

Luo

, et al. Aging-associated excess formaldehyde leads to spatial memory deficits. Sci Rep. 2013;3:1807.

34.

Tong

Han

Luo

, et al. Accumulated hippocampal formaldehyde induces age-dependent memory decline. Age. 2013;35(3):583-596.

35.

Lai

Zuo

. Formation of formaldehyde from adrenaline in vivo; a potential risk factor for stress-related angiopathy. Neurochem Res. 1997;22(5):615-620.

36.

Tong

Wang

Luo

, et al. Urine Formaldehyde Predicts Cognitive Impairment in Post-Stroke Dementia and Alzheimer's Disease. J Alzheimers Dis. 2017;55(3):1031-1038.

37.

Tan

Zhang

Luo

, et al. Formaldehyde induces diabetes-associated cognitive impairments. FASEB J. 2018;32(7):3669-3679.

38.

Dominy

Lynch

Ermini

, et al. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333.

39.

Haditsch

Roth

Rodriguez

, et al. Alzheimer's Disease-Like Neurodegeneration in Porphyromonas gingivalis Infected Neurons with Persistent Expression of Active Gingipains. J Alzheimers Dis. 2020;75(4):1361-1376.

40.

Koskinen

Nevalainen

Karikoski

Hanninen

Jalkanen

Salmi

. VAP-1-deficient mice display defects in mucosal immunity and antimicrobial responses: implications for antiadhesive applications. J Immunol. 2007;179(9):6160-6168.

41.

Rozylo

. The significance of the formaldehyde cycle in the pathology of hard tissues of teeth. Ann Univ Mariae Curie Sklodowska Med. 1997;52:157-159.

42.

Rozylo

Siembida

Nemeth

Albert

Tyihak

. HPLC-OPLC-MS investigation of change of formaldehyde and its generators in human teeth of different physiological stage. Biomed Chromatogr. 2000;14(3):173-179.

43.

Wang

Fau

Liu

, et al. Postoperative cognitive dysfunction is correlated with urine formaldehyde in elderly noncardiac surgical patients. Neurochem Res. 2012;37(10):2125-2134.

44.

Retfalvi

Nemeth

Sarudi

Albert

. Alteration of endogenous formaldehyde level following mercury accumulation in different pig tissues. Acta Biol Hung. 1998;49(2-4):375-379.

45.

Uchikawa

Kanno

Maruyama

, et al. Demethylation of methylmercury and the enhanced production of formaldehyde in mouse liver. J Toxicol Sci. 2016;41(4):479-487.

46.

Panza

Solfrizzi

Logroscino

. Age-related hearing impairment—a risk factor and frailty marker for dementia and AD. Nat Rev Neurol. 2015;11(3):166-175.

47.

Nie

Wei

Chen

, et al. Formaldehyde at low concentration induces protein tau into globular amyloid-like aggregates in vitro and in vivo. PLoS One. 2007;2(7):e629.

48.

Miao

Liu

. Formaldehyde induces hyperphosphorylation and polymerization of Tau protein both in vitro and in vivo. Biochim Biophys Acta Gen Subj. 2013;1830(8):4102-4116.

49.

Zhao

Huang

Tong

. Formaldehyde‐Crosslinked Nontoxic Aβ Monomers to Form Toxic Aβ Dimers and Aggregates: Pathogenicity and Therapeutic Perspectives. Chem Med Chem. 2021;16(22):3376-3390.

50.

Gandbhir

Sundaram

. Effect of AmyTrap, an amyloid-β binding drug, on Aβ induced mitochondrial dysfunction and tau phosphorylation in cultured neuroblastoma cells. Metab Brain Dis. 2020;35(6):923-931.

51.

Wang

Zhou

, et al. The association of mitochondrial aldehyde dehydrogenase gene (ALDH2) polymorphism with susceptibility to late-onset Alzheimer's disease in Chinese. J Neurol Sci. 2008;268(1-2):172-175.

52.

Kou

Zhao

Cui

Han

Tong

. Formaldehyde toxicity in age-related neurological dementia. Ageing Res Rev. 2022;73:101512.

53.

Hou

Dan

Babbar

, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565-581.

54.

Rocha

De Miranda

Sanders

. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiol Dis. 2018;109:249-257.

55.

Jansen van Rensburg

Abrahams

Bardien

Kenyon

. Toxic feedback loop involving iron, reactive oxygen species, α-synuclein and neuromelanin in Parkinson’s disease and intervention with turmeric. Mol Neurobiol. 2021;58(11):5920-5936.

56.

Scudamore

Ciossek

. Increased oxidative stress exacerbates α-synuclein aggregation in vivo. J Neuropathol Exp Neurol. 2018;77(6):443-453.

57.

Abd El-Aal

Abd El-Fattah

El-Abhar

. CoQ10 augments rosuvastatin neuroprotective effect in a model of global ischemia via inhibition of NF-κB/JNK3/Bax and activation of Akt/FOXO3A/Bim cues. Front Pharmacol. 2017;8:735.

58.

Bălașa

Chircov

Grumezescu

. Body Fluid Biomarkers for Alzheimer’s Disease—An Up-To-Date Overview. Biomedicines. 2020;8(10):421.

59.

Tao

Liao

Wang

, et al. In Situ Imaging of Formaldehyde in Live Mice with High Spatiotemporal Resolution Reveals Aldehyde Dehydrogenase-2 as a Potential Target for Alzheimer's Disease Treatment. Anal Chem. 2021.

60.

Ruesink

Reimer

Gregersen

Moeller

Betzer

Jensen

. Stabilization of α-synuclein oligomers using formaldehyde. PLoS One. 2019;14(10):e0216764.

61.

Lee

E-S

Chen

Hardman

Simm

Charlton

. Excessive S-adenosyl-L-methionine-dependent methylation increases levels of methanol, formaldehyde and formic acid in rat brain striatal homogenates: possible role in S-adenosyl-L-methionine-induced Parkinson's disease-like disorders. Life Sci. 2008;83(25-26):821-827.

62.

Lin

Tan

. Effect of ALDH2 on sleep disturbances in patients with Parkinson’s disease. Sci Rep. 2019;9(1):1-8.

63.

Chan

Teng

Moridani

Siraki

O'Brien

. The role of aldehyde dehydrogenase in the prevention of formaldehyde mediated norsalsolinol formation in PC12 cells. J Neurochem. 2003;87(suppl 1):140.

64.

Cai

Cong

Rothman

Maudsley

Martin

. Metabolic Dysfunction in Alzheimer's Disease and Related Neurodegenerative Disorders. Curr Alzheimer Res. 2012.

65.

Tan

Zhang

Luo

, et al. Formaldehyde induces diabetes‐associated cognitive impairments. Faseb J. 2018;32(7):3669-3679.

66.

Aoyama

Matsubara

Okada

, et al. N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test. J Neural Transm. 2000;107(8):985-995.

67.

Tulpule

Dringen

. Formaldehyde in brain: an overlooked player in neurodegeneration? J Neurochem. 2013;127(1):7-21.

68.

Weisskopf

Morozova

O’Reilly

, et al. Prospective study of chemical exposures and amyotrophic lateral sclerosis. Neurosurgery & Psychiatry. 2009;80(5):558-561.

69.

Wang

Sun

Cui

, et al. Acute High‐altitude Hypoxia Exposure causes Neurological Deficits via Formaldehyde Accumulation. CNS Neuroscience & Therapeutics; 2022.

70.

Mahad

Ziabreva

Lassmann

Turnbull

. Mitochondrial defects in acute multiple sclerosis lesions. Brain. 2008;131(7):1722-1735.

71.

Zerin

Kim

J-S

Gil

H-W

Song

H-Y

Hong

S-Y

. Effects of formaldehyde on mitochondrial dysfunction and apoptosis in SK-N-SH neuroblastoma cells. Cell Biol Toxicol. 2015;31(6):261-272.

72.

Ebadi

Govitrapong

Sharma

, et al. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease. Biol Signals Recept. 2001;10(3-4):224-253.

73.

Wang

Huang

, et al. Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy. Park Relat Disord. 2018;57:58-62.

74.

Duberley

KEC

Hargreaves

Chaiwatanasirikul

, et al. Coenzyme Q10 quantification in muscle, fibroblasts and cerebrospinal fluid by liquid chromatography/tandem mass spectrometry using a novel deuterated internal standard. Rapid Commun Mass Spectrom. 2013;27(9):924-930.

75.

Komaki

Faraji

Komaki

, et al. Investigation of protective effects of coenzyme Q10 on impaired synaptic plasticity in a male rat model of Alzheimer’s disease. Brain Res Bull. 2019;147:14-21.

76.

Singh

Brocker

Koppaka

, et al. Aldehyde dehydrogenases in cellular responses to oxidative/electrophilicstress. Free Radic Biol Med. 2013;56:89-101.

77.

Schapira

Reichmann

. Electron transport chain defects in Alzheimer's disease. Neurology. 1995;45(3):599-600.

78.

Stokes

Mahngar

Domazet-Damjanov

Sikorska

Pandey

. Inhibition of stress induced premature senescence in presenilin-1 mutated cells with water soluble Coenzyme Q10. Mitochondrion. 2014;17:106-115.

79.

Tong

Zhang

Luo

, et al. Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. Neurobiol Aging. 2011;32(1):31-41.

80.

Momiyama

. Serum coenzyme Q10 levels as a predictor of dementia in a Japanese general population. Atherosclerosis. 2014;237(2):433-434.

81.

Yao

Bai

, et al. Accumulation of formaldehyde causes motor deficits in an in vivo model of hindlimb unloading. Commun Bio. 2021;4(1):1-13.

82.

Shults

Haas

Beal

. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson’s disease. Biofactors. 1999;9(2-4):267-272.

83.

Kones

. Parkinson's Disease Mitochondrial Molecular Pathology, Inflammation, Statins, and Therapeutic Neuroprotective Nutrition. Nutr Clin Pract. 2010;25(4):371-389.

84.

Borsche

Pereira

Klein

Grunewald

. Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects. J Parkinsons Dis. 2021;11(1):45-60.

85.

Moccia

Capacchione

Lanzillo

, et al. Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis. Therap Adv Neurolol Diss. 2019;12:1756286418819074.

86.

Zavalishin

Dziuba

Khokhlov

Savchenko

. Significance of N-methyl amino acids in the diagnosis and pathogenesis of multiple sclerosis. Vrach Delo. 1987;12(12):68-70.

87.

Khalilian

Madadi

Fattahi

Abouhamzeh

. Coenzyme Q10 enhances remyelination and regulate inflammation effects of cuprizone in corpus callosum of chronic model of multiple sclerosis. Mol Neurobiol. 2021;52(1):125-134.

88.

Soleimani

Jameie

Barati

Mehdizadeh

Kerdari

. Effects of coenzyme Q10 on the ratio of TH1/TH2 in experimental autoimmune encephalomyelitis model of multiple sclerosis in C57BL/6. Iran Biomed J. 2014;18(4):203-211.

89.

Sanoobar

Eghtesadi

Azimi

, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015;18(4):169-176.

90.

Sanoobar

Eghtesadi

Azimi

Khalili

Jazayeri

Reza Gohari

. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing–remitting multiple sclerosis. Int J Neurosci. 2013;123(11):776-782.

91.

Mantle

Heaton

Hargreaves

. Coenzyme Q10, Ageing and the Nervous System: An Overview. Antioxidants. 2021;11(1):2.

92.

Dumont

Kipiani

, et al. Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheim Dis. 2011;27(1):211-223.

93.

Muthukumaran

Kanwar

Vegh

, et al. Ubisol-Q 10 (a nanomicellar water-soluble formulation of CoQ 10) treatment inhibits Alzheimer-type behavioral and pathological symptoms in a double transgenic mouse (TgAPEswe, PSEN1dE9) model of Alzheimer’s disease. J Alzheim Dis. 2018;61(1):221-236.

94.

Durán-Prado

Frontiñán

Santiago-Mora

, et al. Coenzyme Q10 protects human endothelial cells from β-amyloid uptake and oxidative stress-induced injury. PLoS One. 2014;9(10):e109223.

95.

Shults

. Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacol Therapeut. 2005;107(1):120-130.

96.

Schulz

Henshaw

Matthews

Beal

. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995;132(2):279-283.

97.

Hargreaves

Lane

Sleiman

. The coenzyme Q10 status of the brain regions of Parkinson’s disease patients. Neurosci Lett. 2008;447(1):17-19.

98.

Harris

. Vision in Parkinson’s disease: what are the deficits and what are their origins? Neuro Ophthalmol. 1998;19(3):113-135.

99.

Müller

Büttner

Gholipour

A-F

Kuhn

. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003;341(3):201-204.

100.

Beal

Oakes

Shoulson

, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-552.

101.

Lin

Beal

. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787-795.

102.

Mancuso

Orsucci

Volpi

Calsolaro

Siciliano

. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets. 2010;11(1):111-121.

103.

Salama

Yuan

Machado

, et al. Co-enzyme Q10 to treat neurological disorders: basic mechanisms, clinical outcomes, and future research direction. CNS Neurol Disord - Drug Targets. 2013;12(5):641-664.

104.

Henzi

. Chronic methanol poisoning with the clinical and pathologic-anatomical features of multiple sclerosis. Med Hypotheses. 1984;13(11):63-75.

105.

Sanoobar

Dehghan

Khalili

Azimi

Seifar

. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial. Nutr Neurosci. 2016;19(3):138-143.

106.

Shi

Caudle

Zhang

. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis. 2009;35(2):157-164.

107.

Litvan

Halliday

Hallett

, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol. 2007;66(4):251-257.

108.

Morris

Price

. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci. 2001;17(2):101-118.

109.

Gibson

Starkov

Blass

Ratan

Beal

. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim Biophys Acta, Mol Basis Dis. 2010;1802(1):122-134.

110.

Akbar

Essa

Daradkeh

, et al. Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress. Brain Res. 2016;1637:34-55.

111.

Hroudová

Singh

Fišar

. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer’s disease. BioMed Res Int. 2014;2014.

112.

Salehpour

Farajdokht

Cassano

, et al. Near-infrared photobiomodulation combined with coenzyme Q10 for depression in a mouse model of restraint stress: reduction in oxidative stress, neuroinflammation, and apoptosis. Brain Res Bull. 2019;144:213-222.

113.

Zhang

. A Review of the Delivery System of Coenzyme-Q10 Based on Nanotechnology. IOP Conf Ser Earth Environ Sci. 2019;242.

Opposite Roles of Co-enzyme Q10 and Formaldehyde in Neurodegenerative Diseases

Abstract

Keywords

Introduction

Role of Endogenous Formaldehyde in Neurodegenerative Diseases

Formaldehyde and Alzheimer’s disease

Formaldehyde and Parkinson’s Disease

Formaldehyde and Multiple Sclerosis

Role of Endogenous Coenzyme Q10 in Neurodegenerative Diseases

CoQ10 and Alzheimer’s Disease

CoQ10 and Parkinson’s Disease

CoQ10 and Multiple Sclerosis

CoQ10 for Treating Neurodegenerative Diseases

CoQ10 and Alzheimer’s disease

CoQ10 and Parkinson’s Diseases

CoQ10 and Multiple Sclerosis

Summary and Outlook

Footnotes

Declaration of Conflicting Interests

Funding

ORCID iDs

References